AUF GENETISCHEM TARGETING BASIERENDES VERFAHREN ZUR BEHANDLUNG MIT BUCINDOLOL

摘要

The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the ²1-adrenergic receptor (AR).